Ligand Pharma (LGND) Tops Q2 EPS by 60c

Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $37.73 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13